Hi [[ session.user.profile.firstName ]]

Life Sciences

  • Next Frontier in Subvisible Particle Analysis: New Tools and Opportunities
    Next Frontier in Subvisible Particle Analysis: New Tools and Opportunities
    Danny Chou, President and Founder at Compassion BioSolution, and Mark Mark Bumiller, Technology Manager at Entegris. Recorded: May 21 2020 100 mins
    Presented by Danny Chou, President and Founder at Compassion BioSolution, LLC
    Followed by an industry perspective presented by Mark Bumiller, Technology Manager at Entegris.

    In the past decade, we have witnessed the arrival of a large number of analytical technologies that are useful for characterizing sub-visible particles in protein therapeutics. Even with the diverse tools that are available today, there are still important gaps that have not been filled but yet have a significant role in our ability to fully analyze particles for either product characterization or formulation development purpose. The goal of this presentation is to highlight some of these gaps and share the opportunities that may be captured by new tools that are on the horizon. Finally, the speaker will elaborate on how simultaneous monitoring of sub-micron and micron-sized particles can assist biopharmaceutical formulation development and help fulfill current and future regulatory requirements.”
  • Implementation of Functional Diagnostics using Patient-derived Tumor Organoids
    Implementation of Functional Diagnostics using Patient-derived Tumor Organoids
    Dr. Laura Martin Recorded: May 21 2020 35 mins
    Full Title: Implementation of Functional Diagnostics and High Throughput Drug Screening of Patient‐Derived Tumor Organoids

    Intro / 3D Cell Culture: From Promise to Reality: 00:00 – 6:52
    Englander Institute for Precision Medicine Drug Discovery Platform: 6:53 – 10:30
    EIPM tumor organoid platform pipeline: 10:31 – 17:28
    EIPM organoid types: 17:29 – 18:59
    High throughput drug screening Core: 19:00 -23:11
    New tools: CRISPR screening: 23:12 – 25:47
    Tumor microenvironment: 25:48 – 28:55
    Human Cancer Model Initiative / summary: 28:56 – 31:45
    Q&A session: 31:46 - 34:59


    Precision medicine aims to match individual patients with the best treatment based on the patients’ tumors biologic and molecular characteristics. As part of the Englander Institute for Precision Medicine at Weill Cornell Medical College, the Tumor Organoid Platform is an active program focused on the development of Next Generation Cancer Models derived from metastatic and primary anatomic sites obtained through biopsies, surgical resections and rapid autopsy procedures. With this platform, they are able to extend their personalized medicine program to include high throughput drug screening, which can be validated through genomic sequencing and both in vivo and in vitro models.
  • Lung Cancer Diagnostics: Evolving Practice and Future Directions
    Lung Cancer Diagnostics: Evolving Practice and Future Directions
    Professor Keith Kerr Recorded: May 21 2020 61 mins
    Personalized medicine for non-small-cell lung cancer (NSCLC) continues to evolve rapidly, building on a solid diagnostic foundation based on H&E and immunohistochemistry (IHC), incorporating predictive biomarker testing for oncogene-directed therapies and immunotherapies. Understanding the role of biomarker testing, different technologies and latest developments is vitally important for practicing pathologists.

    During this Bright TALK webinar, Professor Keith Kerr will review the current diagnostic pathways in lung cancer, outline the role of IHC and molecular testing, differentiate oncogene biomarkers from immunotherapy biomarkers, and share his perspectives on future directions in lung cancer testing, including multiplexed assays.
  • How to publish with Nursing for Women's Health
    How to publish with Nursing for Women's Health
    Dr. Mary C. Brucker, Editor, Nursing for Women's Health Recorded: May 21 2020 47 mins
    Learn techniques and strategies to publish in Nursing for Women’s Health with editor Dr. Mary C. Brucker. You can expect to learn about developing a manuscript, strategies for getting your work accepted, and common reasons for rejection. During this webinar, Mary will elaborate on what sets Nursing for Women’s Health apart from other journals in this field and the reasons to submit your work to this premium journal. Join this engaging webinar and get an opportunity to also find answers to your questions in the Q&A session during the webinar. You can submit your questions via this link: https://smittalsachdeva.typeform.com/to/lpeD05 and we will aim to answer your questions during the webinar.

    Don’t forget to extend this invitation to your colleagues who might find this of interest.

    About Nursing for Women’s Health:
    Nursing for Women's Health (NWH) is an official journal of the Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN). The mission of NWH is to improve outcomes for women and newborns through the dissemination of clinical scholarship. The journal focuses on evidence-based practice for women's health, childbearing, and neonatal care. The tone of NWH is practical and reader-friendly while upholding high standards for scholarly content.
    NWH publishes a variety of manuscript types, including original research with a clinical focus, reviews, quality improvement projects, practice articles, case reports, continuing nursing education (CNE) articles, health care policy, legislative, or advocacy articles, commentaries, personal essays, and letters to the editor.
  • セルベースアッセイ用プレートの表面処理技術と利用例
    セルベースアッセイ用プレートの表面処理技術と利用例
    コーニングインターナショナル株式会社 ライフサイエンス事業部 江藤哉子 Recorded: May 20 2020 64 mins
    コーニングが有する種々の細胞培養表面は、長年に渡り培ってきた技術とノウハウの蓄積を元に開発されてきました。培養例を含めながらラインナップをご紹介します。
  • Produção de Vacinas: Soluções Corning em Bioprocesso
    Produção de Vacinas: Soluções Corning em Bioprocesso
    Luiz Gustavo Mendes Recorded: May 19 2020 56 mins
    Luiz Gustavo Mendes, MSc, Field Application Scientist - Corning LifeSciences Biólogo, mestrado em Tecnologia de Imunobiológicos com experiência de 11 anos no desenvolvimento de vacinas
  • Addressing Questions & Unmet Needs in Melanoma Research and Treatment
    Addressing Questions & Unmet Needs in Melanoma Research and Treatment
    Marc Hurlbert; Tom Williams Recorded: May 19 2020 60 mins
    The landscape for melanoma research and treatment has rapidly changed over the last decade. Since 2011, the FDA has approved 12 new melanoma treatment regimens – including new classes of drugs that are molecularly targeted therapies (BRAF/MEK inhibitors), immune checkpoint inhibitors (anti CTLA-4, PD-1/PD-L1) and other immunotherapies (e.g. T-Vec). Scientists have also unraveled many of the genomic mutations found in the most common form, cutaneous melanoma, melanoma that arises primarily on sun-exposed areas of the skin. With these advances in research and treatment, the key unanswered questions have changed rapidly and existing preclinical models may not be sufficient to answer such questions surrounding immune checkpoint inhibition; resistance development, comparing to cuaneous melanoma, and how to improve early detection.

    Importantly, there are no models that accurately predict the patient journey. New models and additional research is needed to more fully represent all melanoma subtypes, stages, or treatment responses.

    About the speakers:
    Marc Hurlbert, Ph.D. Chief Science Officer, Melanoma Research Alliance. Marc is currently responsible for guiding MRA’s scientific strategy, overseeing the peer-reviewed grant-making program, and forging scientific collaborations. He has more than 18 years of nonprofit and grant-making experience focused on advancing medical research. Past work has included treatment and prevention strategies for breast cancer, lymphoma and multiple myeloma, as well as juvenile diabetes.

    Tom Williams, PhD, Life Sciences Professional Services Project Manager, Elsevier. Tom is a Life Sciences Knowledge Manager and Research Scientist. with extensive experience as an academic researcher in neurodegeneration and Alzheimer’s disease. He is also in skilled biophysical chemistry, dementia disorders, and biochemistry; and the author of many publications in the field of Alzheimer’s disease.
  • Continuous Manufacturing as a Default Platform for Oral Solid Drug Products
    Continuous Manufacturing as a Default Platform for Oral Solid Drug Products
    Lawrence De Belder, Senior Principal Engineer at j&J and Bob Lenich, Director of Life Sciences Business at Emerson Recorded: May 19 2020 99 mins
    Presented by Lawrence De Belder, Senior Principal Engineer Continuous Manufacturing at Johnson and Johnson

    Followed by an Industry Perspective presented by Bob Lenich, Director of Life Sciences Business at Emerson

    The counter is at Six today: Orkambi, Symdeko, Trikafta (Vertex); Prezista (Johnson and Johnson); Verzenio (Eli Lilly); Daurismo (Pfizer) –are all approved by the FDA – Johnson and Johnson’s Tramacet for the Japanese market not included. Several large Pharma companies have chosen the path of Continuous Manufacturing, and announced they will use this platform as their default for development and consequently – commercial manufacturing of their Oral Solid dose drug product pipeline.

    During this webinar, the author will explain the consequences of this decision, and different strategies to handle a pipeline that can be highly dynamic. Different techniques will be discussed that can be used to bring products with bad flow properties into a continuous process. Impact of different equipment in development, clinical and commercial environment will be detailed out, and mitigations will be proposed to overcome these differences. All will be placed in front of a background of regulatory requirements, changing market demand, and evolving strategies of equipment vendors.
  • Vaccine Production and R&D with Corning Solutions – A New Approach
    Vaccine Production and R&D with Corning Solutions – A New Approach
    Constanza Curotto Recorded: May 19 2020 53 mins
    Vaccines are considered to be one of the biggest public health achievements of the past century. Vaccines act by initiating the innate immune response when activating antigen presenting cells, inducing a protective response towards a pathogen. These agents may contain live attenuated, inactivated, or only parts of a pathogen.

    Corning provides diverse single-use products for upstream vaccine manufacturing needs reducing the cost and minimizing the labor per titer.

    This webinar provides background information about the main forms of vaccine design, R&D, and manufacturing workflows, data generated in Corning’s application labs and vaccine considerations for COVID-19.
  • Final Revised Version of BioPhorum Extractable Testing Recommendation Part 1
    Final Revised Version of BioPhorum Extractable Testing Recommendation Part 1
    Frances Sexton, Carsten Worsøe, Ken Wong, and Satish Kumar Mohanvelu Recorded: May 18 2020 104 mins
    Since the first publication of Biophorum (previously known as BPOG) Extractable Testing Recommendation in 2014, the combined team of end-users and suppliers has collaborated to examine all improvement opportunities to the original extractable testing recommendation since 2017. During this webinar, the presenters will highlight all the changes to the final revised version of Biophorum Extractable Testing Recommendation. Specifically, the output of a data review of 26 extractable data sets spanning wide varieties of single use components, which has led to the changes to be made in the original recommendation, will be presented.

    The revised extractable testing recommendation will be presented to highlight:

    1 End-users and suppliers collaboration set up;

    2 Specific updates to the extraction study recommendation;

    3 Specific areas of flexibility when implementing the protocol;

    4 Updates to the analytical test method system suitability;

    To facilitate a harmonized extractable data reporting to end users, the presenters will introduce the newly designed Biophorum Extractable Data Summary (BEDS) template. Some levels of details with regards to what specific information or format of templates are compulsory and what are flexible for supplier to tailor to their own preferences will be detailed during the webinar. How end users can gain access to these extractable summary reports from suppliers, including subsuppliers, will be addressed.

    Additionally, several FAQs questions will be presented to clarify some common questions. The webinars will end with 30 minutes of a panel discussion for participants to seek clarify of all presented information.
  • Partner Ecosystem and the ‘Importance of Our Community'
    Partner Ecosystem and the ‘Importance of Our Community'
    Wayne Arvidson, Director, Global Edge Partner and Industries Office, Safety and Security | Computer Vision Recorded: May 14 2020 30 mins
    In today’s world of Digital Transformation, Safety and Security | Computer Vision capabilities are front and center. Whether it’s edge computing, artificial intelligence and machine learning at the edge, core or cloud, see how your organization can deploy next generation safety and security solutions.
    Join Wayne Arvidson, Director, Global Edge Partner and Industries Office, Safety and Security | Computer Vision, Dell Technologies for this live webinar.

    What’s in It for You
    •Gain insights into industry trends and game changers driven by a dynamic community.
    •Explore emerging safety and security use cases and learn how Dell and our partners make them real today.
    •Hear how Dell Technologies brings together different partners and input from the community to improve and design new solutions.
  • Assessing the Risk of Interaction Between Extractables and Leachable and Ther...
    Assessing the Risk of Interaction Between Extractables and Leachable and Ther...
    Andrew Teasdale, Senior Principal Scientist at AstraZeneca and Piet Christieans, Phd,Scientific Director at Nelson Labs Recorded: May 14 2020 94 mins
    FULL TITLE: Assessing the Risk of Interaction Between Extractables and Leachable and Therapeutic Proteins

    Presented by Andrew Teasdale, Senior Principal Scientist Impurity management and External Advocacy at AstraZeneca

    Biologics and Peptides often present their own challenges in respect to leachables. They are typically administered parenterally and therefore there is a high risk of interaction between dosage form and packaging / administration system. They are often low dose and sensitive to structural modifications, this can impact Safety (immunogenicity), Quality (instability, aggregation) and Efficacy (loss of potency). This webinar will examine the potential risk factors through case study examples including reactive leachables, the impact of sterilisation and adverse events and their route cause. It will conclude by looking at opportunities to look predictively at potential issues and how this can be incorporated into product design

    Followed by Piet Christieans, Phd,Scientific Director at Nelson Labs
  • It’s in the blood: Patient-derived hematologic malignancy models in research
    It’s in the blood: Patient-derived hematologic malignancy models in research
    Amy Wesa, PhD, Director of Immuno-Oncology Research, Champions Oncology Recorded: May 14 2020 35 mins
    Hematological malignancies are cancers that begin in the cells of blood-forming tissue or in the cells of the immune system. These types of cancer, specifically, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are on the rise in the aging population globally. In this webinar, Dr. Wesa will demonstrate how patient-derived hematologic malignancy in vivo and ex vivo models can be used to advance drug development.

    Viewing this webinar will help you to:
    •Develop an understanding of a robust approach to human AML Patient-derived Xenograft (PDX) in vivo models
    •Learn how to select study endpoints for in vivo and ex vivo models
    •Learn how to advance early stage compounds through Champions’ hematologic Vitroscreen for AML, B-ALL and MCL Disease indications
  • Techniques for Publishing in Transformative Ground-Breaking Journals
    Techniques for Publishing in Transformative Ground-Breaking Journals
    Dr. Lewis Collins, Editor-in-Chief, One Earth (A Cell Press journal) Recorded: May 14 2020 76 mins
    Learn techniques and strategies for publishing in transformative ground-breaking journals with Dr. Lewis Collins, Editor-in-Chief of One Earth (a Cell Press journal). Dr. Collins will share tips on developing your papers for ground-breaking publications, elaborate on his experience of working with researchers and authors throughout the research publishing cycle and the opportunity to broadly disseminate findings. Dr. Collins will also share more details about the growth of Cell Press journals in the physical and environmental sciences field, including the launch of many new titles such as Chem, Matter, Joule, and One Earth. He’ll outline Cell Press’ approach to high-demand, multi-disciplinary content, and expanding OA publishing strategies at Cell Press. Join this engaging webinar to find the answers to your pressing questions in the Q&A session during the webinar. Don’t forget to extend this invite to your colleagues who might find this of interest.

    About Lewis Collins:
    Inspired by David Attenborough documentaries as a child, Lewis has been amazed by the natural world from an early age. While undergraduate and master’s degrees in Earth science (Cardiff University), and Climate Change (University of East Anglia) nurtured this interest, it was doctoral (British Antarctic Survey) and post-doctoral (Université Pierre et Marie Curie) research on Antarctica that centered his focus on environmental change. Prior to launching One Earth, Lewis spent over 5 years with Nature Communications, where he led the Earth editorial team and curated, commissioned, handled (and occasionally rejected…) research across the full spectrum of Earth and environmental science. Lewis is particularly interested in grand challenges associated with land-use and the competing demands for this increasingly scarce resource.
  • Affinity Chromatography for Vaccines Purification
    Affinity Chromatography for Vaccines Purification
    Mikkel Nissum, Vaccine R&D Quality Site Lead at GSK Vaccines Recorded: May 12 2020 46 mins
    Presented by Mikkel Nissum, Vaccine R&D Quality Site Lead at GSK Vaccines

    Only clean drinking water rivals vaccination in its ability to save lives. Yet, development and manufacturing of vaccines remain challenging. Vaccines comprise a heterogeneous variety of targets. Each target requires a dedicated development and manufacturing process adding to the timelines for getting new vaccines to the patient and to ensure a reliable supply. For the downstream processing part, often the process is composed of an optimized set of up to three chromatographic steps to provide the final desired quality of the target. On top of the long development time required to develop such a multi-step process, at times, the end result may not be satisfactory, in particular regarding purity of the target.
    In order to overcome this downstream processing challenge, we embarked on establishing a purification platform based on affinity purification. The main advantages of such a platform for vaccine manufacturing would be:
    1)By applying a positive selection principle for chromatography, the number of chromatographic steps may be reduced to just one step
    2)Establishing a platform would require minimal process changes from one target to another
    3)Downstream processing would become predicable in terms of development time and costs
    The journey of establishing the affinity purification platform focusing on main challenges and key results will be presented in the Webinar.
  • Understanding genome-wide NIPT
    Understanding genome-wide NIPT
    Dr. Liza Kunz and Jen Kaplan, LCGC Recorded: May 12 2020 57 mins
    Cell-free DNA prenatal test menus have rapidly expanded in recent years to address not only the common trisomies, but also sex chromosome aneuploidies, copy number variants, and rare autosomal trisomies. However, “more” is not necessarily “better”. Potential benefits to patients must be carefully weighed against potential harms before tests are introduced into clinical practice. Please join us for an in-depth examination of clinical considerations and implications of expanded cfDNA test menus.
  • How to Prepare Your Manuscripts for Publication in Top Journals
    How to Prepare Your Manuscripts for Publication in Top Journals
    Kavitha Scranton, Ph.D., Senior Scientific Editor, Immunity (Cell Press) Recorded: May 12 2020 79 mins
    Would you like to learn tips for writing and developing a strong narrative for your work? Do you want advice on how to prepare your manuscripts for publication in the best journal for your research? Join us for a webinar with Kavitha Scranton, Ph.D., Senior Scientific Editor at Immunity (Cell Press) to learn techniques and strategies to set yourself up for publishing success. Kavitha will share tips on developing your manuscript (with a special focus on researchers based in the Turkey/ME region), elaborate on her experience working with researchers throughout the publishing cycle, and highlight opportunities to broadly disseminate your research findings. Kavitha will also share more details about the growth of multidisciplinary Cell Press journals. Join this engaging webinar and get answers to your questions in the Q&A session. Don’t forget to extend this invitation to your colleagues who might find this of interest.

    About Kavitha Scranton:
    Kavitha Scranton received her Ph.D. in Immunology from the University of Massachusetts Medical School, where she studied the development and function of γδ T cells in the laboratory of Dr. Joonsoo Kang. She conducted her postdoctoral research at the Broad Institute of MIT and Harvard on T cell-mediated autoimmunity in the laboratory of Dr. Ramnik Xavier. In 2015, Kavitha joined Immunity as a scientific editor.
  • Advanced 3D Applications and Tips for Optimizing Your 3D Assays
    Advanced 3D Applications and Tips for Optimizing Your 3D Assays
    Hilary Sherman, Senior Scientist Recorded: May 7 2020 60 mins
    This webinar will discuss advanced 3D cell culture applications that will include organoids, immune oncology, and screening in 3D cell culture. Additionally, it will review tips and tricks for optimizing 3D cell culture assays covering topics such as scaffold and scaffold free solutions, automation and various assay outputs.

    1:59 - 8:16: Overview: Why/What 3D?
    8:17 - 15:17: 3D Co-culture
    15:18 - 24:42: Spheroid models with Transwell® Permeable Supports
    24:43 - 29:17: Screening with Corning® Matrigel® Matrix
    29:18 - 40:09: Optimizing Spheroid Formation
    40:10 - 44:10: Working with ECMs
    44:11 - 49:23: Optimizing Spheroid Processing
    50:01 - 59:03: Q&A Session
  • Clinical decision support in the NGS Oncology workflow
    Clinical decision support in the NGS Oncology workflow
    Dr. Stephanie Yaung Recorded: May 7 2020 56 mins
    The increasing adoption of next generation sequencing (NGS) in molecular profiling of cancer presents a need for streamlined result interpretation in clinical labs. With growing complexity of NGS results, evolving guidelines, and fragmented data sources, clinical decision support (CDS) systems can facilitate reporting of clinically relevant variants. In this talk, our speaker will discuss how software capable of automatically interpreting and presenting clinically relevant information reduces the need for time-consuming and error-prone manual curation.
  • Optimizing clinical trial design with extracted efficacy data
    Optimizing clinical trial design with extracted efficacy data
    Marnix Wieffer Recorded: May 7 2020 46 mins
    Around 90% of the small molecule drugs that enter clinical trials do not make it to the market. Therefore, optimizing clinical trial design and reducing late stage failures are key priority for drug developers.

    With Phase II efficacy-related failure rates as high as 57%, many companies are seeking ways to improve their outcomes and reduce the climbing $2.6 billion costs to get one drug to market. As clinical trials become increasingly more complex and costly, is even more critical to mitigate the risk of failed clinical trials or arms due to suboptimal study design or poor efficacy

    Join us for this 45-minute webinar where Customer Consultant drug safety Jean-Dominique Pierret and Drug Safety Marketing Manager Dr. Marnix Wieffer will discuss how using PharmaPendium we can uncover critical information to make better more informed clinical development decisions.

    This will include in-depth information and demonstrations of how to leverage the comparative data in PharmaPendium to reduce the risk of late-stage failures. With a focus on efficacy, we will discuss how PharmaPendium enables you to:

    •Find efficacy weaknesses early
    •Identify the most appropriate preclinical models,
    •Improve success rates of Phase I and II clinical trial designs by optimising selection of sample size
    •Primary/secondary endpoint and study design and
    •Prepare for more effective regulatory reviews
  • Image Search for Pan-Cancer Diagnostic Consensus
    Image Search for Pan-Cancer Diagnostic Consensus
    Hamid Tizhoosh, Director KIMIA Lab at the University of Waterloo Recorded: May 6 2020 31 mins
    Join Hamid Tizhoosh, Director of the KIMIA Lab at the University of Waterloo in Canada, as he discusses how large and representative reference databases of diagnosed cases can assist pathologists in performing “virtual peer reviews.”
  • Machine Learning in Bioprocess Development: Where We Are and Where We Could Go
    Machine Learning in Bioprocess Development: Where We Are and Where We Could Go
    Rui Portela and Klaus Mauch, CEO at Insilico Biotechnology AG Recorded: May 6 2020 84 mins
    Machine Learning is believed to be a game changer for industry, especially by big Pharma as reflected by significant investments. Starting from an introduction to machine learning, this contribution outlines the current machine learning status for process development with examples, provides future directions towards more global high-value machine learning centric development, concepts to engage people in the digital evolution and ideas for machine learning centric business models.

    Presented by Rui Portela, Senior Data Scientist, GlaxoSmithKline Vaccines

    Rui Portela works as Senior Data Scientist at Global Data Analytics and Innovation group in Technical R&D of GSK Biologicals, Belgium. He is a molecular and cell biologist, with a MSc in biotechnology from the New University of Lisbon (UNL) and PhD in Bioengineering Systems (MIT-Portugal program – UNL). Previously, Rui worked on model based bioprocess optimization at GSK and IBET as research scientist, applying metabolic network analysis, PAT, simulation of molecular processes and hybrid modeling methods to enable more efficient process operation/design.

    And Klaus Mauch, CEO at Insilico Biotechnology AG

    Klaus Mauch is one of Insilico’s co-founders and became managing director in 2004 and CEO in 2006. In his previous role as CTO, he was responsible for the design and development of Insilico’s modelling and simulation platform where he established novel methods for the computer-aided construction of cellular networks. Before that, he gained extensive experience in metabolic engineering and applied systems biology as a group leader at the Institute of Biochemical Engineering, University of Stuttgart. Klaus is a member of the Advisory Board of the Division Systems Biology and Synthetic Biology of DECHEMA, board member of the Industrial Association White Biotechnology (IWBio), and board member of the Association of German Biotechnology Companies (VBU).
  • New Drying Processes for Biopharmaceuticals
    New Drying Processes for Biopharmaceuticals
    Sune Klint Andersenand Principal Scientist at Janssen Pharmaceutical and Lars Markwort, co-founder and CEO of Bioinicia SL Recorded: May 5 2020 91 mins
    Presented by Sune Klint Andersen, Principal Scientist at Janssen Pharmaceutical Companies of Johnson & Johnson

    Sune Klint Andersen is Principal Scientist for Spray Drying at the Janssen Pharmaceutical Companies of Johnson & Johnson. He has a Ph.D. in Chemical Engineering. He has worked with pharmaceutical spray drying for 17 years within process development for R&D and commercial scale, application of Quality-by-Design and PAT, particle engineering, drying kinetics, aseptic spray drying and advantages and disadvantages of spray vs freeze drying processes. He previously worked at Novo Nordisk for 7 years.

    and followed by Lars Markwort, co-founder and CEO of Bioinicia SL


    Lars Markwort is co-founder and CEO of Bioinicia SL. He holds a Ph.D. in Chemistry and worked for 20 years in the analytical and process equipment industry, supplying mainly the semiconductor and pharmaceutical industries. At Bioinicia he is guiding the scaling up of electrohydrodynamic processes to industrial production with a focus on drying, micronization and encapsulating of labile bioactives for applications in pharmaceuticals and nutraceuticals.
  • The Future of Safety & Security
    The Future of Safety & Security
    Nick Thermenos, General Manager, Safety and Security | Computer Vision, Dell Technologies Recorded: Apr 30 2020 30 mins
    Join Nick Thermenos, General Manager, Safety and Security | Computer Vision, Dell Technologies for an interactive webinar on the Future of Safety and Security | Computer Vision solutions as organizations are working to make the world safer. With the growing number of cameras and requirements to retain videos for a longer time period, organizations are looking to update their existing infrastructure to run optimally and scale cost-efficiently.
  • Designing Cytometry Assays for IO Applications: The Do's, Don'ts & Don't Forgets
    Designing Cytometry Assays for IO Applications: The Do's, Don'ts & Don't Forgets
    Dr. Tamara Laskowski, Senior Research Scientist of MD Anderson Cancer Center Recorded: Apr 30 2020 61 mins
    For many researchers flow cytometry can be overwhelming and confusing, especially if this is a technique is not used every day. In this webinar, Dr. Tamara Laskowski, of MD Anderson Cancer Center, will share her expertise in working to develop practical flow cytometry assays in the Immuno-Oncology area.

    Register for this webinar to learn:
    •The requirements for design and development of cytometry-based assays
    •Strategies for increasing reproducibility of flow cytometry assays
    •Important considerations when designing cytometry-based assays for immuno-oncology studies
  • Chemistry Data for Systems Thinkers
    Chemistry Data for Systems Thinkers
    Paul Dockerty May 26 2020 2:00 pm UTC 75 mins
    Systems thinking has become an essential part of modern medicinal chemistry and new drug development (1). Dealing with the increasing data volumes, information silos and low interoperability has become one of the biggest challenges to medicinal chemists when trying to take a holistic approach to identify the interactions and hidden connections within the organelles, cells, tissues, organisms. Often, we wonder:

    “Am I seeing the big picture without losing insight of the details?”

    In this webinar, we will discuss how to take a system approach to create new chemistry knowledge, to translate knowledge into useful applications and finally to be ready to face the unfolding world crises (2). The topics include
    - Systematic integration of biological and chemical data;
    - AI-ready data for synthesis route design and prediction;
    - Three practical examples using system thinking examples, including
    1. digitalization of chemistry knowledge in pharmaceutical industry,
    2. responding to COVID-19 pandemic using conscientious data excerption from literature,
    3. data readiness in green chemistry to support sustainability.

    Change management and education are inevitably critical to pursuing systems thinking approach, therefore we will talk about some best practices for pharmaceutical industry and educational system based on our learning's from the collaborative projects.

    (1) Systems Thinking for Medicinal Chemists, Jacobs Journal of Medicinal Chemistry, 2015, I (1),004
    (2) One-world chemistry and systems thinking, Nature Chemistry, 2016, 8, 393–398

    Paul Dockerty, PhD, is a Customer Engagement Manager in the Professional Services group at Elsevier, now responsible for supporting pharmaceutical customers in their digitalization journey. He is passionate about using data as a leverage to fight the natural resistance to change in digital transformations.
  • New Trends and Future Directions in Catalysis
    New Trends and Future Directions in Catalysis
    Frances Arnold, Lutz Ackermann, Corinna Schindler, and Douglas W. Stephan May 26 2020 2:00 pm UTC 105 mins
    The field of catalysis in chemistry was historically dominated by the use of transition metal catalysts. Due to a unique set of properties, precious metals in particular have played an integral role in developing catalysts for new modes of chemical bond activation and formation. One major and inherent drawback of precious metals, however, is their scarcity; in order to transition chemistry to a more sustainable use of the world’s limited resources, finding alternative strategies for catalysis is a major driving force in contemporary research. In this spirit, this webinar will feature talks about four areas of sustainable catalysis from leaders in their respective fields, highlighting state-of-the-art approaches and providing guidance for future developments in these areas of research.

    Speaker Information:

    Frances Arnold is Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry, and Director of the Donna and Benjamin M. Rosen Bioengineering Center at Caltech. She received the Nobel Prize in Chemistry in 2018 for directed enzyme evolution.

    Lutz Ackermann is a Professor at the Georg-August-University Göttingen. The development and application of novel concepts for sustainable catalysis constitutes his major current research interest, and he has a topical focus on C–H activation.

    Corinna Schindler is an Associate Professor at the University of Michigan. The research interests of her laboratory include the synthesis of complex molecules and the development of new synthetic transformations between carbonyls and alkenes.

    Douglas W. Stephan is a Professor at the University of Toronto and a world-leading researcher in inorganic chemistry/catalysis and the founder of the field of “frustrated Lewis pair” (FLP) chemistry. He has received many national and international awards, including Humboldt and Killam Fellowships.
  • COVID-19 May Briefing: The UK&I Healthcare Ecosystem Fightback
    COVID-19 May Briefing: The UK&I Healthcare Ecosystem Fightback
    Professor Shafi Ahmed, Divya Chadha Manek, Rt Hon Stephen Dorrell, Angela McFarlane, Sarah Rickwood, Paul Tunnah (moderator) May 27 2020 11:30 am UTC 75 mins
    Insights on the impact of COVID-19 for pharma and biotech companies and considerations for a post-coronavirus new normal in life sciences and healthcare.

    It will also discuss the UK response to the emergency, clinical trials and how digital health has met the COVID-19 challenge for healthcare professionals, patients and industry.
  • Light/Matter Interactions: Illuminating Materials and Researchers
    Light/Matter Interactions: Illuminating Materials and Researchers
    Lea Nienhaus, Raffaella Buonsanti, and Bozhi Tian May 27 2020 2:00 pm UTC 120 mins
    The interactions between light and matter have been widely studied for applications in energy, bioelectronics, and catalysis, among others. These applications are heavily reliant on precise synthesis and materials characterization in order to fundamentally understand the physics, chemistry, and biology that drive the observed phenomena.

    In this webinar, Lea Nienhaus, Raffaella Buonsanti, and Bozhi Tian discuss their efforts in studying light/matter interactions from different disciplinary backgrounds. In addition to their scientific insights, they will speak about their ongoing broader engagement with the scientific community and strong advocacy for mentoring, outreach, and science communication. Specifically, during a panel discussion, they will address how they have tried to keep engaged during this time away from the lab.

    About the speakers:

    Lea Nienhaus, Assistant Professor, Florida State University

    Lea Nienhaus obtained her PhD from the University of Illinois at Urbana-Champaign. Since 2018, the Nienhaus group has pioneered the application of bulk perovskite sensitizers in photon upconversion, and they are currently working on unraveling the complex photophysical processes occurring in these devices.

    Raffaella Buonsanti, Assistant Professor, EPFL

    Raffaella Buonsanti started her position as Tenure Track Assistant Professor at the Institute of Chemical Sciences and Engineering (ISIC) of the École Polytechnique Fédérale de Lausanne (EPFL) in November 2015. Through their core expertise in colloidal synthesis, her team develops novel approaches to creating complex materials to drive chemical transformations.

    Bozhi Tian, Associate Professor, University of Chicago

    Bozhi Tian received his Ph.D. degree in physical chemistry from Harvard University in 2010. He is currently an associate professor at the University of Chicago and working on semiconductor-enabled fundamental studies of subcellular biophysics and soft matter dynamics.
  • Automatically populate your IR: Harvesting Scopus data into Digital Commons
    Automatically populate your IR: Harvesting Scopus data into Digital Commons
    Shandon Quinn, VP Product Management, Digital Commons; Martin Edling Andersson, Principal Product Manager, Scopus May 27 2020 3:00 pm UTC 45 mins
    “The IR is meant to be as complete and comprehensive as possible.” – IR administrator, R1 public university

    One of the primary purposes of the IR is to serve an institution’s faculty, by representing their works comprehensively. And yet, this is one of the hardest, most burdensome challenges for IR managers.

    In this webinar, get a next-level look at the upcoming Scopus-Digital Commons integration to automatically populate your IR at scale with faculty publication records. The presentation walks viewers through the following features:
    - Ease of use – no technical skills required
    - Record deduplication of IR faculty research content
    - Auto population of upload spreadsheets
    - Flagging OA content

    We’ll also demonstrate the value of Scopus data and let you know how Digital Commons customers will be provided with access to Scopus data as part of the release launch.

    Learn how this new tool can save IR managers up to 75% of the time it takes to add faculty publication records into their IR.
  • Multiply Your Cells, Not Your Work: How to Upscale Adherent Cells [GER. VERSION]
    Multiply Your Cells, Not Your Work: How to Upscale Adherent Cells [GER. VERSION]
    Dr. Franziska Wienholz May 28 2020 9:00 am UTC 30 mins
    The Life Sciences Rendez-vous : Bioprocess, Adherent Cells - PART 1/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 2, Part 3 and other languages on our webinar page.

    Efficient cell scale-up is essential in biologics production; cell type, application, and space dictate the most suitable technology for an application. In this webinar, we will provide an overview of Corning cell culture vessels for adherent cells, and how those can be employed for cell upscaling for bioproduction applications such as vaccine manufacture, upscaling cell therapies, and viral vector production.

    About Presenter:

    Dr. Franziska Wienholz
    Franziska completed her Ph.D. in Molecular Genetics at the Erasmus MC,The Netherlands, focusing on studying DNA repair and related diseases. During her research, she acquired extensive knowledge on cell culture and patient-derived materials, molecular techniques, and genome editing.
    Franziska joined Corning in 2017 and in her role as Bioprocess Sales Specialist, she is currently supporting customers with technical questions and product selection in the bioprocess field. Additionally, she provides training on Corning applications and solutions in the form of webinars and scientific seminars.
  • Multiply Your Cells, Not Your Work: How to Upscale Adherent Cells [FR. VERSION]
    Multiply Your Cells, Not Your Work: How to Upscale Adherent Cells [FR. VERSION]
    Dr. Nicolas André May 28 2020 12:00 pm UTC 30 mins
    The Life Sciences Rendez-vous : Bioprocess, Adherent Cells - PART 1/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 2, Part 3 and other languages on our webinar page.

    Efficient cell scale-up is essential in biologics production; cell type, application, and space dictate the most suitable technology for an application. In this webinar, we will provide an overview of Corning cell culture vessels for adherent cells, and how those can be employed for cell upscaling for bioproduction applications such as vaccine manufacture, upscaling cell therapies, and viral vector production.

    About Presenter:

    Dr. Nicolas André
    Nicolas received his Ph.D. from the University of Frankfurt/Main, in 2006, after studying membrane protein biochemistry at the Max Planck institute of biophysics, under the supervision of Hartmut Michel, 1988 Chemistry Nobel prize. He completed his training with a postdoc research project on membrane protein interaction in CNRS Marseille.
  • Flow Cytometry: Validation and Implementation in a Regulatory Setting
    Flow Cytometry: Validation and Implementation in a Regulatory Setting
    Chelsea Riveley, MBA, Head of Business Development, Flow Cytometry Services May 28 2020 1:00 pm UTC 60 mins
    This webinar provides an overview of flow cytometry and its potential uses in the regulatory setting. Two case studies will be presented to detail the unique aspects of conducting flow cytometry in both a preclinical and clinical regulated setting. The following phases of developing and validating a robust and reliable flow cytometry assay will be illustrated in this webinar: The critical steps to any flow cytometry assay – panel design, assay development, descriptions of validation test scripts that should be conducted along with suitable acceptance criteria, proper instrument set-up and appropriate controls, gating strategy and identification of cell subsets, and correct interpretation of flow cytometry data. Lastly, what to look for when choosing an outsourcing partner for flow cytometry will be discussed. These include some of the key decision points and factors to consider such as expertise, regulatory requirements, logistics, timelines, and price.
  • Multiply Your Cells, Not Your Work: How to Upscale Adherent Cells [ENG. VERSION]
    Multiply Your Cells, Not Your Work: How to Upscale Adherent Cells [ENG. VERSION]
    Dr. Lindsey Parker May 28 2020 2:00 pm UTC 30 mins
    The Life Sciences Rendez-vous : Bioprocess, Adherent Cells - PART 1/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 2, Part 3 and other languages on our webinar page.

    Efficient cell scale-up is essential in biologics production; cell type, application, and space dictate the most suitable technology for an application. In this webinar, we will provide an overview of Corning cell culture vessels for adherent cells, and how those can be employed for cell upscaling for bioproduction applications such as vaccine manufacture, upscaling cell therapies, and viral vector production.

    About Presenter:

    Dr. Lindsey Parker
    Lindsey completed her Ph.D. in Tissue Engineering and Regenerative Medicine at the University of Leeds (UK), validating a bioreactor for the application of mechanical stimuli to MSC. She subsequently joined UCL as an industrial KTP associate, leading clinical research in umbilical cord- derived MSC scale-up in collaboration with a tissue bank.
  • Modern Uses of Thermal Imaging and Computer Vision Technologies
    Modern Uses of Thermal Imaging and Computer Vision Technologies
    Michael Knight, Global CTO, Safety and Security – Industry Edge, Dell Technologies May 28 2020 3:00 pm UTC 30 mins
    Welcome back to Dell Technologies Innovation Webinar Series. In this conversation we will explore and focus on the “Modern Uses of Thermal Imaging and Computer Vision Technologies”. The next generation of safety and security solutions such as thermal imaging and computer vision are being used in novel ways in today’s world, and we believe this is only the beginning.
  • The Future of Batteries
    The Future of Batteries
    Kelsey Hatzell, Yifei Mo, and Nella Vargas-Barbosa May 28 2020 3:00 pm UTC 105 mins
    The importance of more than 40 years of research on lithium-ion batteries was recognized with the 2019 Nobel Prize in Chemistry. As the world is moving toward electrification and the greater use of renewable energy, the question that researchers have been looking to answer is what is the next lithium-ion battery? In this session, three early career researchers who are helping to shape the future of battery research will provide their perspectives on solid-state batteries. The talks will address crucial aspects of developing solid-state batteries, ranging from materials discovery to operando characterization. This webinar aims to highlight innovative work that has the potential to shape the direction of future battery research and development.

    About the speakers:

    Kelsey Hatzell is an assistant professor in mechanical and chemical engineering at Vanderbilt University, Nashville, USA. Her research group focuses on understanding transport at solid|solid and solid|liquid interfaces for a range of applications related to energy storage, conversion, and separations applications.

    Yifei Mo is an associate professor of materials science and engineering at the University of Maryland, College Park, USA. Dr. Mo’s research aims to advance the understanding, design, and discovery of engineering materials through cutting-edge computational techniques, with current emphases on new materials for energy storage and conversion.

    Since January 2019, Nella Vargas-Barbosa is a junior group leader in the nanochemistry department at the Max Planck Institute for Solid State Research in Stuttgart, Germany. Her research interests focus on the electrochemical characterization of interfaces with applications in energy storage and conversion.
  • Content and Manuscript Submission Tips for JOGNN
    Content and Manuscript Submission Tips for JOGNN
    Dr. Patricia Robin McCartney, Associate Editor, Journal of Obstetric, Gynecologic & Neonatal Nursing May 28 2020 4:00 pm UTC 45 mins
    Learn more about the Journal of Obstetric, Gynecologic & Neonatal Nursing from Dr. Patricia Robin McCartney, Associate Editor. In this engaging webinar, Dr. McCartney will share information about JOGNN, the JOGNN audience, and what to consider before submitting your manuscript for publication consideration in JOGNN. You will learn about the criteria for reporting clinical projects in manuscripts for the Health Care Improvement and Evaluation category. Dr. McCartney will also provide advice on preparing your manuscript, editorial style, the publishing process, and resources available to support authors.

    This webinar includes the opportunity to ask questions during the Q&A session. Don’t forget to extend the invite to your colleagues and friends who may find this of interest.

    You can also submit your questions via this link: https://smittalsachdeva.typeform.com/to/lpeD05

    About JOGNN (Journal of Obstetric, Gynecologic & Neonatal Nursing):
    JOGNN is an official journal of the Association of Women’s Health, Obstetric and Neonatal Nurses, and a premier resource to advance the health and health care of women, childbearing families, and newborns through the publication of peer-reviewed nursing and interdisciplinary scholarship. With a focus on nursing practice, JOGNN publishes the latest research, reviews, methods, clinical projects, practice issues, case reports, commentaries, resources for evidence-based practice, and policies related to the care of women, childbearing families, and newborns. This peer-reviewed scientific and technical journal is highly respected for groundbreaking articles on important - and sometimes controversial - issues. Articles published in JOGNN emphasize research evidence and clinical practice, building both science and clinical applications. JOGNN seeks research and clinical manuscripts on the evidence supporting current best practice as well as developing or emerging practice trends.
  • Qualidade e Acreditação em Laboratórios-Uma Abordagem da Influência da Vidraria
    Qualidade e Acreditação em Laboratórios-Uma Abordagem da Influência da Vidraria
    Jeronimo Figueiredo Jun 2 2020 5:00 pm UTC 60 mins
    Jeronimo Figueiredo, Business Operations - Latin America, Engenheiro Químico, Corning Life Sciences
  • Advanced Raman Spectroscopy Beyond In-Process Glucose Control of Commercial Cell
    Advanced Raman Spectroscopy Beyond In-Process Glucose Control of Commercial Cell
    Dan Hill, Manufacturing Scientist at Biogen Jun 3 2020 2:00 pm UTC 105 mins
    Full Title:Advanced Raman Spectroscopy Beyond In-Process Glucose Control of Commercial Cell Culture Processes

    Presented by Dan Hill, Manufacturing Scientist at Biogen

    The use of in-line Raman spectroscopy as an in-line process analytical technology (PAT), in the biotechnology industry, has matured over the past decade from a technology with promise to a standard tool for real-time, continuous monitoring of cell culture processes. There is an ever-growing body of work demonstrating successful application from metabolite and product quality monitoring to process control in both process development and GMP manufacturing environments. This is due, in part, to advances in technology robustness, user- and integration-interfaces, improved sensitivity, and fluorescence rejection. Organizations are now faced with the difficult task of best leveraging these tools and extracting the most value from them. Thus, defining and executing Raman program strategy is critical to the technology’s long-term success and sustainability.

    This presentation will describe Biogen’s past efforts and strategic direction as it relates to in-line Raman spectroscopy for cell culture operations and how we intend to leverage its capability beyond metabolite monitoring and glucose feedback control to become an essential element of our Advanced Process Control efforts.
  • Organoids Masterclass Series: Introduction to/Getting Started with Organoids
    Organoids Masterclass Series: Introduction to/Getting Started with Organoids
    Hilary Sherman Jun 3 2020 4:00 pm UTC 60 mins
    Join us for the latest webinar in our Organoids Masterclass Series. Our presenter, Hilary Sherman will review the following:

    •Traditional Preclinical Models
    •Organoid Technology
    •Organoid Applications
    •Culture Tips and Tricks

    About the Presenter:
    Hilary Sherman is a Senior Scientist in the Corning Life Sciences Applications Lab located in Kennebunk, ME. Hilary has been with Corning Incorporated since 2005 and has worked with a wide variety of cell types including mammalian, insect, primary, stem cells and organoids in a vast array of applications. Her key roles at Corning involve creating technical documents such as protocols and whitepapers as well as providing technical support and training for both the Corning sales force and customers. Hilary received her B.S. degree in Biology from the University of New Hampshire. In the last several years, Hilary has focused on 3D cell culture applications including human organoid culture
  • Bioprocess Suspension Solutions - Suspension Workflow [GER. VERSION]
    Bioprocess Suspension Solutions - Suspension Workflow [GER. VERSION]
    Dr. Franziska Wienholz Jun 4 2020 9:00 am UTC 30 mins
    The Life Sciences Rendez-vous : Bioprocess, Suspension - PART 2/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 3 and other languages on our webinar page.

    Careful vessel selection at all scales enhances space efficacy, reducing cost and labor hours. Suspension processes play a key role in the biopharmaceuticals market, where suspension cell systems are used to produce antibodies and recombinant proteins. This webinar will provide an overview of Corning's suspension culture portfolio, relevant to both R&D and production scenarios, supported by experimental data from our global applications team.

    About Presenter:

    Dr. Franziska Wienholz
    Franziska completed her Ph.D. in Molecular Genetics at the Erasmus MC,The Netherlands, focusing on studying DNA repair and related diseases. During her research, she acquired extensive knowledge on cell culture and patient-derived materials, molecular techniques, and genome editing.
  • Bioprocess Suspension Solutions - Suspension Workflow [FR. VERSION]
    Bioprocess Suspension Solutions - Suspension Workflow [FR. VERSION]
    Dr. Sonia Meconi Jun 4 2020 12:00 pm UTC 30 mins
    The Life Sciences Rendez-vous : Bioprocess, Suspension - PART 2/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 3 and other languages on our webinar page.

    Careful vessel selection at all scales enhances space efficacy, reducing cost and labor hours. Suspension processes play a key role in the biopharmaceuticals market, where suspension cell systems are used to produce antibodies and recombinant proteins. This webinar will provide an overview of Corning's suspension culture portfolio, relevant to both R&D and production scenarios, supported by experimental data from our global applications team.

    About Presenter:

    Dr. Sonia Meconi
    Sonia’s scientific background covers different fields such as biochemistry, cell biology, and immunology where she obtained a Ph.D., specifically in human infectious diseases working on a daily basis in a biologic level 3 lab. After a post-doctoral fellow and lecturer experience, she took over the head of the R&D and production teams in a small biotech which developed human serological diagnosis assays for infectious and autoimmune diseases. She oversaw pathogens (bacteria and virus) expansion supervision for protein microarray tests. Then, she joined an international company as an Application Specialist for cell culture and purification, creating new cell culture media dedicated to vaccines and cell therapy markets. Now, she joined Corning as Bioprocess Specialist working for different suppliers for the biopharmaceutical industry.
  • Bioprocess Suspension Solutions - Suspension Workflow [ENG. VERSION]
    Bioprocess Suspension Solutions - Suspension Workflow [ENG. VERSION]
    Constanza Curotto Jun 4 2020 2:00 pm UTC 30 mins
    The Life Sciences Rendez-vous : Bioprocess, Suspension - PART 2/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 3 and other languages on our webinar page.

    Careful vessel selection at all scales enhances space efficacy, reducing cost and labor hours. Suspension processes play a key role in the biopharmaceuticals market, where suspension cell systems are used to produce antibodies and recombinant proteins. This webinar will provide an overview of Corning's suspension culture portfolio, relevant to both R&D and production scenarios, supported by experimental data from our global applications team.

    About Presenter:

    Constanza Curotto
    After graduating from Biochemistry in the University of Santiago (Chile), Constanza pursued directly a career in the Chilean Vaccine R&D industry, developing as a bioprocess scientist for both bacterial and viral vaccines in the field of animal health, being in charge of scale-up, and tech transfer with manufacturing plants. She furthered developed her career in Belgium as a bioprocess scientist, this time in the field of recombinant protein production, pursuing protocol optimization and scale-up experiments with suspension mammalian cell lines. Constanza is currently a field applications scientist in Corning for the EMEA region, providing customers with in-depth technical support, presenting seminars and trainings, and assisting customers in experimental set-up and troubleshooting.
  • How SwissQPrint Brought Field Operations Up to the Next Level with Tech Content
    How SwissQPrint Brought Field Operations Up to the Next Level with Tech Content
    Johannes Müller, Bruno Fraissinede, Alex Masycheff Jun 4 2020 3:00 pm UTC 60 mins
    Providing excellent customer service that keeps your customers happy without driving up service costs is always a challenge.

    It becomes even more critical when you have thousands of customers and their number is growing. How can you scale your business and still make customer service cost-efficient?

    Join DITAToo and Fluid Topics for a webinar we are conducting with SwissQprint, a maker of high-end digital printing systems, and learn how SwissQprint:

    * Restructured their customer service into field service and training department.

    * Realized that PDFs were not efficient in providing customers and service teams with relevant and useful information.

    * Provided customers and field operations with self-service platforms for delivering personalized content on spare parts and product documentation.

    * Provided service engineers with access to the most up-to-date product information.

    * Changed the service culture from "call for solution" to "information self-service".

    * Received return-on-investment and additional benefits.

    Presenters:

    * Johannes Müller, Head of Technical Communication and Quality Management at swissQprint

    * Bruno Fraissinede, Sales Manager at Antidot, makers of FluidTopics

    * Alex Masycheff, CEO at Intuillion, makers of DITAToo DITA CCMS
  • Learn how Lancet editors decide which papers to accept for publication
    Learn how Lancet editors decide which papers to accept for publication
    Heather Van Epps, Editor-in-Chief The Lancet Rheumatology Jun 4 2020 3:00 pm UTC 69 mins
    Hear Heather Van Epps, Editor-in-Chief of The Lancet Rheumatology, to learn about techniques and strategies for preparing your paper to submit to high-impact journals.

    Heather shares her experiences working with researchers and authors throughout the research publishing cycle. You can expect to learn about how to develop papers for submission to publications like the Lancet family of journals.

    Due to high engagement, we're making the webinar recording available to you. And don't forget to download your manuscript checklist from the resources section.
  • Next Generation Humanized Mice for AML and NK Cell Therapy Testing
    Next Generation Humanized Mice for AML and NK Cell Therapy Testing
    Amy Wesa, PhD, Director of Immuno-Oncology Research at Champions Oncology Jun 8 2020 9:00 pm UTC 55 mins
    To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, of Champions Oncology Inc, will discuss how complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models. View this webinar to learn: The latest advances in human immune system mouse models for oncology therapeutics The power of primary patient-derived models for acute myeloid leukemia (AML) Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice
  • The Use of Multi-species Organoids
    The Use of Multi-species Organoids
    Dr. Valentina Ubertini Jun 9 2020 2:00 pm UTC 45 mins
    Title: The Use of Multi-species Organoids as a Pre-clinical Screen to Assess Gastrointestinal Toxicity

    The small intestinal organoid model (Sato, et al. 2009) incorporates many of the physiologically relevant features of the in vivo intestinal epithelium, including the presence of all the differentiated cell types and the regenerative progenitor cells. We have validated the organoid model as a screening tool to predict GI toxicity (a common and often severe dose-limiting side effect of chemotherapy) and subsequent mucosal regeneration in four species: mouse, rat, canine and human. Using minimal amounts of drug candidates, these assays are much quicker to perform than in vivo models but have been shown to be highly predictive of the in vivo response. Readouts can include viability and proliferation, but also can include more detailed mechanistic information via gene expression profiling (Next Generation Sequencing), immunohistochemistry, in situ hybridisation (RNAscope), and cytokine profiling.

    Speaker Bio:
    Dr Valentina Ubertini completed her Ph.D. researching the relationship between p53 and the anti-inflammatory cytokine sIL-1Ra at Regina Elena National Cancer Institute, Rome, Italy. She then moved to the Cancer Research UK Manchester Institute to investigate the regulation of inflammatory genes modulating the prostate cancer microenvironment. This experience, using a variety of 3D cell culture models (organoids, spheroids) of both primary cells and cell lines, led her to Epistem, Manchester, UK (a company with a history of providing a range of high quality pre-clinical gastrointestinal research services), to lead a team developing a range of intestinal organoid assays as predictive toxicity screens for novel therapeutics.
  • Introdução ao Cultivo de Células 3D
    Introdução ao Cultivo de Células 3D
    Luiz Gustavo Mendes Jun 9 2020 5:00 pm UTC 60 mins
    Luiz Gustavo Mendes, MSc Field Applications Scientist Corning LifeSciences
  • An optimal Environment Across All Stages of Cell Culture [GER. VERSION]
    An optimal Environment Across All Stages of Cell Culture [GER. VERSION]
    Dr. Franziska Wienholz Jun 10 2020 9:00 am UTC 30 mins
    The Life Sciences Rendez-vous : Bioprocess, Media and Sera - PART 3/3.
    Attend our new compact webinars series (30min) in your local language.
    See Part 1, Part 2 and other languages on our webinar page.

    Media and Sera are crucial components in cell culture – providing nutrition such as inorganic salts, amino acids and vitamins, or growth factors to your cells – and optimal products should be carefully selected.
    This webinar presents an overview of Corning’s media and sera portfolio, and how these may enhance both production and research in bioprocess applications.
    Corning’s media and serum offering includes:
    •Many different formulations of standard media to meet specific applications
    •Serum- free and specialty media
    •Standard and premium origin sera
    •A choice of specialty sera and treatments for optimal cell culture and assay performance
    Join this webinar for an overview of how our media and sera can fit into your workflow.

    About presenters:

    Dr. Franziska Wienholz
    Franziska completed her Ph.D. in Molecular Genetics at the Erasmus MC,The Netherlands, focusing on studying DNA repair and related diseases. During her research, she acquired extensive knowledge on cell culture and patient-derived materials, molecular techniques, and genome editing.
  • Computer Programs for Semi-Automation of Evidence Synthesis
    Computer Programs for Semi-Automation of Evidence Synthesis
    Farhad Shokraneh Jun 10 2020 1:00 pm UTC 60 mins
    While all types of literature review are becoming reasonably more attractive for students, researchers, practitioners and policy makers the workload involved in all types of evidence synthesis should not be underestimated. Apart from standardization of procedures and methods, many organizations and collaborations started using computers to reduce the workload and save time in processing all types of reviews. Systematic reviews and meta-analyses, scoping reviews, rapid reviews, overviews, and realist reviews are only some members of review family that can benefit from using computer programs. The research, innovations, discussions, and skepticism around and surrounding the automation became so important that some of automation pioneers started International Collaboration for Automation of Systematic Reviews (ICASR) https://icasr.github.io/. The current webinar will also benefit the outcome of ICASR annual meetings.

    Despite emergence and listing of hundreds of tools in Systematic Review Toolbox (http://systematicreviewtools.com/), these software programs are underused. This webinar will introduce some of these programs alongside the evidence supporting their use and will provide a guide on how to choose the program, when to use them, what are their advantages and disadvantages, and why we should use them. There are automation tools for searching, screening, extracting data, analysis, and report writing. The presentation will also discuss the reasons for underusing problem and its solutions and will justify the fact that automation of evidence synthesis is still an idealist dream and why semi-automation of evidence synthesis is more realistic horizon for in the next decades.